Antibe Therapeutics Inc.
ATE
株式のランク
#31892
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
株価
$0.21483059
最終同期: 2024-05-07
時価総額
$11.13M
変化（1日）
0.34%
変化（1年）
-0.36%
国
CA
取引 Antibe Therapeutics Inc. (ATE)
カテゴリー
Healthcare
Antibe Therapeutics Inc.（ATE）の利益
2026 時点の利益 TTM: 0
Antibe Therapeutics Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Antibe Therapeutics Inc. の利益の推移（2026 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $7.51B | - |
US
|
|
| $5.56B | - |
IE
|
|
| $5.15B | - |
US
|
|
| $3.86B | - |
US
|
|
| - | - |
DE
|
